Immunohistochemistry Market - Global Forecast 2026-2032

The Immunohistochemistry Market is projected to reach USD 3.53 Billion in 2026. It is expected to continue growing at a CAGR of 6.16%, reaching USD 5.07 Billion by 2032.

Immunohistochemistry (IHC) remains a core technology in tissue-based diagnostics, translational research, and precision oncology because it localizes protein expression within preserved cellular architecture. In routine pathology, IHC supports tumor classification, biomarker confirmation, infectious disease evaluation, autoimmune pathology, and therapy selection, making it indispensable to hospital laboratories, reference laboratories, pharmaceutical developers, and contract research organizations.

Demand is reinforced by the sustained global cancer burden. The International Agency for Research on Cancer reported approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, underscoring the need for accurate tissue diagnostics. In breast cancer, IHC-based estrogen receptor, progesterone receptor, and HER2 testing guides clinical decision-making; in lung, gastric, urothelial, cervical, and other cancers, PD-L1 and mismatch repair protein evaluation increasingly inform immunotherapy eligibility. This convergence of oncology care, companion diagnostics, and digital pathology is positioning the immunohistochemistry ecosystem for continued strategic investment.

Transformative Shifts in the IHC Landscape

The IHC landscape is shifting from standalone staining workflows toward integrated diagnostic ecosystems that combine automated staining platforms, validated antibody portfolios, image management, laboratory information systems, and quality assurance programs. Laboratories are prioritizing reproducibility, turnaround time, and regulatory compliance as biomarker complexity increases across oncology, neuropathology, infectious disease, and inflammatory disorders.

A major transformation is the rise of companion diagnostics and therapy-linked biomarkers. Regulatory-approved IHC assays for targets such as HER2, PD-L1, ALK, and mismatch repair proteins have increased the strategic importance of assay validation, pre-analytical control, and pathologist training. At the same time, multiplex IHC and spatial biology approaches are expanding the ability to evaluate immune contexture, tumor microenvironment, and co-expression patterns, supporting both clinical trial enrichment and drug development programs.

Operationally, automation is reshaping procurement decisions. High-throughput staining systems, standardized antigen retrieval, ready-to-use antibodies, and digital slide review reduce variability across institutions. These changes favor suppliers that can provide end-to-end workflow reliability, robust technical support, and evidence-based assay performance across diverse tissue types.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force in immunohistochemistry by improving quantification, consistency, and workflow prioritization. AI-assisted image analysis can support scoring of membrane, nuclear, and cytoplasmic biomarkers, helping laboratories manage interobserver variability in assays such as Ki-67, ER, PR, HER2, PD-L1, and tumor-infiltrating lymphocyte assessment. These tools do not replace the pathologist; they function as decision-support systems that require clinical validation, governance, and quality control.

The impact is strongest when AI is paired with whole-slide imaging and standardized staining. Digital pathology adoption has accelerated in leading health systems and pharmaceutical research settings, while regulators in major markets increasingly expect transparent validation, performance documentation, and human oversight. In drug development, AI-enabled IHC analysis can improve patient stratification, quantify biomarker heterogeneity, and generate reproducible endpoints for clinical trials.

However, adoption depends on data quality, scanner compatibility, algorithm generalizability, cybersecurity, and reimbursement clarity. Industry leaders that build interoperable, explainable, and clinically validated AI workflows will be best positioned to convert digital pathology investments into measurable diagnostic and research value.

Key Regional Insights

North America leads IHC adoption through advanced pathology infrastructure, strong oncology research funding, recognized companion diagnostics, and high utilization of automated staining and digital pathology platforms. The United States drives clinical and commercial momentum through integrated cancer centers, reference laboratories, and pharmaceutical biomarker programs, while Canada benefits from organized cancer care networks, academic pathology excellence, and publicly coordinated oncology services.

Europe demonstrates mature immunohistochemistry utilization, supported by national healthcare systems, European Union regulatory harmonization, external quality assessment programs, and strong pathology research in Germany, France, Italy, Spain, and the United Kingdom. The region’s focus on quality assurance, CE-marked diagnostics, and cross-border clinical research strengthens adoption of standardized IHC assays, although implementation may vary by reimbursement, workforce capacity, and laboratory digitization levels.

Asia-Pacific is a fast-evolving regional opportunity as China, India, Japan, South Korea, Australia, and ASEAN markets expand cancer screening, hospital infrastructure, precision medicine initiatives, and access to oncology biomarker testing. Japan and South Korea have highly advanced diagnostic ecosystems, China is scaling IHC across large hospital networks and cancer centers, and India is improving access through private diagnostics and tertiary oncology institutions. Latin America is advancing through Brazil and Mexico, where demand is supported by rising oncology caseloads, private laboratory modernization, and expanding access to biomarker-guided cancer care. The Middle East, particularly GCC countries, is investing in specialty hospitals, cancer centers, and laboratory automation as part of broader health system modernization, while Africa’s immunohistochemistry market is emerging through academic medical centers, international health partnerships, cancer registry development, and gradual pathology capacity building.

Key Group Insights

Within ASEAN, immunohistochemistry growth is linked to expanding hospital networks, medical tourism, and increasing cancer diagnostic capacity in Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. Singapore serves as a regional reference hub for advanced pathology, clinical trials, and molecular diagnostics, while larger ASEAN countries are scaling access to automated tissue diagnostics in urban tertiary centers and private laboratory networks.

The GCC is investing in oncology care, specialist hospitals, and laboratory modernization as governments prioritize noncommunicable disease management and localized healthcare capacity. These investments support adoption of automated IHC, companion diagnostics, and digital pathology, especially in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait. The European Union remains a high-value group due to harmonized regulatory expectations, public cancer programs, external quality assessment practices, and strong diagnostic manufacturing and clinical research capabilities.

BRICS countries represent volume-driven expansion, led by China and India with large patient populations, growing oncology infrastructure, and increasing precision medicine adoption, while Brazil, Russia, and South Africa contribute demand through public and private healthcare systems with varying levels of reimbursement and laboratory capacity. G7 markets remain innovation leaders because of established reimbursement pathways, academic cancer centers, validated companion diagnostic use, and pharmaceutical research intensity. NATO-aligned markets, particularly in North America and Europe, benefit from resilient healthcare infrastructure, advanced laboratory networks, biomedical research funding, and shared emphasis on diagnostic quality and health security.

Key Country Insights

The United States is the most influential IHC market due to high cancer testing volume, FDA-approved companion diagnostics, extensive reference laboratory networks, academic cancer centers, and major pharmaceutical biomarker programs. Canada follows with strong academic pathology, publicly organized cancer services, and increasing digital pathology adoption. Mexico and Brazil are advancing through private diagnostics, tertiary hospitals, and demand for oncology biomarker testing, although access can vary by payer, region, and public-sector laboratory capacity.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain robust immunohistochemistry utilization through established pathology systems, national cancer strategies, external quality programs, and participation in multicenter clinical trials. Germany benefits from advanced laboratory automation and diagnostics manufacturing capabilities, France has strong translational oncology programs, Italy and Spain show broad clinical uptake across public hospitals, and the United Kingdom is expanding digital pathology through health system modernization initiatives. Russia maintains demand through large hospital networks and oncology programs, though procurement and technology access may be influenced by geopolitical and supply-chain constraints.

In Asia-Pacific, China is scaling IHC through large tertiary hospitals, cancer centers, and domestic diagnostics development. India is expanding through private laboratory chains, oncology hospitals, medical education initiatives, and growing awareness of biomarker-driven treatment. Japan remains highly advanced in precision diagnostics, quality assurance, and oncology drug development, while South Korea combines strong hospital infrastructure with rapid digital health adoption and clinical research activity. Australia benefits from high diagnostic standards, national cancer care initiatives, external quality assessment participation, and early adoption of digital pathology in select networks.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated antibody portfolios, automated workflow compatibility, and evidence-backed assay performance across diverse tissue specimens. As IHC becomes more tightly linked to treatment selection, suppliers must invest in quality assurance, lot-to-lot consistency, regulatory documentation, and pathologist education.

Laboratories should standardize pre-analytical processes, including fixation time, tissue processing, antigen retrieval, and scoring protocols, to reduce variability. Health systems can improve turnaround time and diagnostic confidence by integrating automated staining, digital slide management, and validated AI-assisted quantification where appropriate.

Pharmaceutical and diagnostics organizations should expand co-development strategies for companion diagnostics, particularly in immuno-oncology, breast cancer, gastrointestinal cancers, lung cancer, and emerging spatial biology applications. In high-growth markets, success will depend on local technical support, reagent affordability, training programs, and partnerships with cancer centers and reference laboratories.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with market intelligence best practices. Inputs include publicly available information from international health agencies, cancer registries, regulatory bodies, clinical guidelines, peer-reviewed pathology literature, healthcare infrastructure indicators, and publicly accessible product and technical documentation.

The analysis emphasizes verified trends rather than speculative claims. Regional and country-level interpretations are derived from observable healthcare capacity, oncology burden, regulatory maturity, diagnostic adoption patterns, quality assurance practices, and the presence of academic, hospital, and reference laboratory networks. Insights are synthesized to support strategic decision-making for manufacturers, laboratories, healthcare providers, pharmaceutical organizations, and investors in the immunohistochemistry ecosystem.

Conclusion

Immunohistochemistry continues to be a foundational technology for modern pathology, with expanding relevance in precision oncology, companion diagnostics, drug development, and digital pathology. Rising cancer incidence, broader biomarker utilization, and the need for reproducible tissue-based evidence are strengthening demand across mature and emerging markets.

The next phase of differentiation will be shaped by automation, validated antibody performance, AI-assisted image analysis, multiplex assays, spatial biology, and integrated diagnostic workflows. Organizations that combine scientific credibility with scalable operations, regulatory readiness, and regional adaptability will be best positioned to capture long-term opportunities in the global IHC ecosystem.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunohistochemistry Market, by Product Category

7.1. Introduction
7.2. Antibodies
7.2.1. Primary Antibodies
7.2.1.1. Monoclonal
7.2.1.2. Polyclonal
7.2.1.3. Recombinant Monoclonal
7.2.1.4. Recombinant Fragments
7.2.2. Secondary Antibodies
7.2.2.1. Enzyme-Conjugated
7.2.2.2. Biotinylated
7.2.2.3. Fluorophore-Conjugated
7.2.2.4. Unconjugated
7.3. Detection Systems
7.3.1. Polymer
7.3.2. Avidin-Biotin
7.3.3. Tyramide Amplification
7.4. Chromogens & Counterstains
7.4.1. DAB
7.4.2. AEC
7.4.3. Fast Red
7.4.4. Hematoxylin
7.5. Ancillary Reagents
7.5.1. Retrieval Buffers
7.5.2. Blocking Reagents
7.5.3. Wash Buffers
7.6. Kits & Panels
7.6.1. Single-Marker Kits
7.6.2. Multiplex Panels

8. Immunohistochemistry Market, by Technology

8.1. Introduction
8.2. Chromogenic IHC
8.2.1. HRP/DAB
8.2.2. AP/Red
8.2.3. Dual Enzyme
8.3. Immunofluorescence
8.3.1. Singleplex IF
8.3.2. Multiplex IF
8.4. Signal Amplification
8.4.1. Tyramide Signal Amplification
8.4.2. Biotin-Based Amplification
8.5. Metal-Conjugated IHC
8.5.1. Mass Cytometry-Compatible
8.5.2. MIBI-Compatible

9. Immunohistochemistry Market, by Specimen Type

9.1. Introduction
9.2. FFPE Tissue
9.2.1. Resection
9.2.2. Biopsy
9.3. Frozen Tissue
9.4. Cytology Specimens
9.4.1. Smears
9.4.2. Liquid-Based Preparations
9.5. Tissue Microarrays

10. Immunohistochemistry Market, by Application

10.1. Introduction
10.2. Clinical Diagnostics
10.2.1. Oncology
10.2.1.1. Solid Tumors
10.2.1.2. Hematopathology
10.2.2. Infectious Disease
10.2.3. Transplant Immunopathology
10.2.4. Neuropathology
10.2.5. Cardiovascular Pathology
10.2.6. Companion Diagnostics
10.3. Research & Drug Discovery
10.3.1. Basic Research
10.3.2. Translational Research
10.3.3. Target Validation
10.3.4. Biomarker Discovery
10.3.5. Toxicologic Pathology
10.4. Veterinary Pathology
10.5. Forensic Pathology
10.6. Education & Training

11. Immunohistochemistry Market, by Indication

11.1. Introduction
11.2. Oncology
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Colorectal Cancer
11.2.4. Prostate Cancer
11.2.5. Melanoma
11.2.6. Lymphoma
11.2.7. Brain Tumors
11.3. Infectious Diseases
11.3.1. Viral
11.3.2. Bacterial
11.3.3. Fungal
11.4. Autoimmune & Inflammatory
11.4.1. Systemic Autoimmune
11.4.2. Gastrointestinal Inflammatory
11.5. Neurological Disorders
11.6. Renal & Hepatic
11.6.1. Renal Disease
11.6.2. Hepatic Disease

12. Immunohistochemistry Market, by End User

12.1. Introduction
12.2. Hospital Laboratories
12.2.1. Community Hospitals
12.2.2. Academic Medical Centers
12.3. Reference Laboratories
12.4. Academic & Research Institutes
12.5. Pharmaceutical & Biotechnology
12.5.1. In-House Labs
12.5.2. Outsourced Partners
12.6. Contract Research Organizations
12.7. Veterinary Pathology Laboratories

13. Immunohistochemistry Market, by Region

13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa

14. Immunohistochemistry Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Immunohistochemistry Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Agilent Technologies Inc.
17.2. Becton, Dickinson & Company
17.3. Bio SB
17.4. Bio-Rad Laboratories Inc.
17.5. Bio-Techne Corporation
17.6. Biocare Medical LLC
17.7. Biogenex Laboratories
17.8. CANDOR Bioscience GmbH
17.9. Cell Signaling Technology, Inc.
17.10. Danaher Corporation
17.11. Diagnostic BioSystems Inc.
17.12. Eagle Biosciences, Inc.
17.13. Elabscience Biotechnology Inc.
17.14. F. Hoffman-La Roche AG
17.15. Genemed Biotechnologies, Inc. =
17.16. Histo-Line Laboratories
17.17. Lunaphore Technologies SA
17.18. Merck KGaA
17.19. Miltenyi Biotec B.V. & Co. KG
17.20. PerkinElmer Inc.
17.21. Rockland Immunochemicals, Inc.
17.22. Takara Bio, Inc
17.23. Thermofisher Scientific, Inc.

List of Figures

FIGURE 1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2032 (%)
FIGURE 7. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL IMMUNOHISTOCHEMISTRY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PRIMARY ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PRIMARY ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PRIMARY ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MONOCLONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MONOCLONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MONOCLONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL POLYCLONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL POLYCLONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL POLYCLONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL RECOMBINANT MONOCLONAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL RECOMBINANT MONOCLONAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL RECOMBINANT MONOCLONAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL RECOMBINANT FRAGMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL RECOMBINANT FRAGMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL RECOMBINANT FRAGMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SECONDARY ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL SECONDARY ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL SECONDARY ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL ENZYME-CONJUGATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ENZYME-CONJUGATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ENZYME-CONJUGATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL BIOTINYLATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BIOTINYLATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BIOTINYLATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL FLUOROPHORE-CONJUGATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL FLUOROPHORE-CONJUGATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL FLUOROPHORE-CONJUGATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL UNCONJUGATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL UNCONJUGATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL UNCONJUGATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL DETECTION SYSTEMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DETECTION SYSTEMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL DETECTION SYSTEMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POLYMER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL POLYMER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL POLYMER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL AVIDIN-BIOTIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL AVIDIN-BIOTIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL AVIDIN-BIOTIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL TYRAMIDE AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL TYRAMIDE AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL TYRAMIDE AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CHROMOGENS & COUNTERSTAINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL CHROMOGENS & COUNTERSTAINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL CHROMOGENS & COUNTERSTAINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL DAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL DAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL AEC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL AEC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL AEC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL FAST RED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL FAST RED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL FAST RED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL HEMATOXYLIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HEMATOXYLIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HEMATOXYLIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ANCILLARY REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ANCILLARY REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ANCILLARY REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RETRIEVAL BUFFERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RETRIEVAL BUFFERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RETRIEVAL BUFFERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL BLOCKING REAGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL WASH BUFFERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL WASH BUFFERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL WASH BUFFERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL KITS & PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL KITS & PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL KITS & PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SINGLE-MARKER KITS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SINGLE-MARKER KITS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SINGLE-MARKER KITS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL MULTIPLEX PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL MULTIPLEX PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL MULTIPLEX PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CHROMOGENIC IHC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CHROMOGENIC IHC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CHROMOGENIC IHC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL HRP/DAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL HRP/DAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HRP/DAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL AP/RED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL AP/RED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL AP/RED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL DUAL ENZYME MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL DUAL ENZYME MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL DUAL ENZYME MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL IMMUNOFLUORESCENCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SINGLEPLEX IF MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SINGLEPLEX IF MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SINGLEPLEX IF MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL MULTIPLEX IF MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL MULTIPLEX IF MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL MULTIPLEX IF MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL SIGNAL AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL SIGNAL AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL SIGNAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL TYRAMIDE SIGNAL AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL TYRAMIDE SIGNAL AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL TYRAMIDE SIGNAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL BIOTIN-BASED AMPLIFICATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL BIOTIN-BASED AMPLIFICATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL BIOTIN-BASED AMPLIFICATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL METAL-CONJUGATED IHC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL METAL-CONJUGATED IHC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL METAL-CONJUGATED IHC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL MASS CYTOMETRY-COMPATIBLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL MASS CYTOMETRY-COMPATIBLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL MASS CYTOMETRY-COMPATIBLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL MIBI-COMPATIBLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL MIBI-COMPATIBLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL MIBI-COMPATIBLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL FFPE TISSUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL FFPE TISSUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL FFPE TISSUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL RESECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL RESECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL RESECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL FROZEN TISSUE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL FROZEN TISSUE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL FROZEN TISSUE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL CYTOLOGY SPECIMENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL CYTOLOGY SPECIMENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL CYTOLOGY SPECIMENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL SMEARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL SMEARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL SMEARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL LIQUID-BASED PREPARATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL LIQUID-BASED PREPARATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL LIQUID-BASED PREPARATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL TISSUE MICROARRAYS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL TISSUE MICROARRAYS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL TISSUE MICROARRAYS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL HEMATOPATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL HEMATOPATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 162. GLOBAL HEMATOPATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 163. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 164. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 166. GLOBAL TRANSPLANT IMMUNOPATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. GLOBAL TRANSPLANT IMMUNOPATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. GLOBAL TRANSPLANT IMMUNOPATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 169. GLOBAL NEUROPATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. GLOBAL NEUROPATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 171. GLOBAL NEUROPATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL CARDIOVASCULAR PATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. GLOBAL CARDIOVASCULAR PATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 174. GLOBAL CARDIOVASCULAR PATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 175. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL RESEARCH & DRUG DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 179. GLOBAL RESEARCH & DRUG DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL RESEARCH & DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL BASIC RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 182. GLOBAL BASIC RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. GLOBAL BASIC RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 184. GLOBAL TRANSLATIONAL RESEARCH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 185. GLOBAL TRANSLATIONAL RESEARCH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. GLOBAL TRANSLATIONAL RESEARCH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 187. GLOBAL TARGET VALIDATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL TARGET VALIDATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. GLOBAL TARGET VALIDATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 190. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. GLOBAL BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 193. GLOBAL TOXICOLOGIC PATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 194. GLOBAL TOXICOLOGIC PATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. GLOBAL TOXICOLOGIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 196. GLOBAL VETERINARY PATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 197. GLOBAL VETERINARY PATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. GLOBAL VETERINARY PATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 199. GLOBAL FORENSIC PATHOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 200. GLOBAL FORENSIC PATHOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 201. GLOBAL FORENSIC PATHOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 202. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 204. GLOBAL EDUCATION & TRAINING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 205. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 206. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 207. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 209. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 210. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 211. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 212. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 213. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 215. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 216. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 217. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 218. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 219. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 220. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 221. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 222. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 223. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 225. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 226. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 227. GLOBAL BRAIN TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 228. GLOBAL BRAIN TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. GLOBAL BRAIN TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 230. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 231. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 232. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 233. GLOBAL VIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 234. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 236. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 237. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 238. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 239. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 240. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 241. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 242. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 243. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 244. GLOBAL AUTOIMMUNE & INFLAMMATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 245. GLOBAL SYSTEMIC AUTOIMMUNE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 246. GLOBAL SYSTEMIC AUTOIMMUNE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 247. GLOBAL SYSTEMIC AUTOIMMUNE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 248. GLOBAL GASTROINTESTINAL INFLAMMATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 249. GLOBAL GASTROINTESTINAL INFLAMMATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 250. GLOBAL GASTROINTESTINAL INFLAMMATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 251. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 252. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 253. GLOBAL NEUROLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 254. GLOBAL RENAL & HEPATIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 255. GLOBAL RENAL & HEPATIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 256. GLOBAL RENAL & HEPATIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 257. GLOBAL RENAL DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 258. GLOBAL RENAL DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 259. GLOBAL RENAL DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 260. GLOBAL HEPATIC DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 261. GLOBAL HEPATIC DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 262. GLOBAL HEPATIC DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 263. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 265. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 266. GLOBAL HOSPITAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 267. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 268. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 269. GLOBAL COMMUNITY HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 270. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 271. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 272. GLOBAL ACADEMIC MEDICAL CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 273. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 274. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 275. GLOBAL REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 276. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 277. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 278. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 279. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 280. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 281. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 282. GLOBAL IN-HOUSE LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 283. GLOBAL IN-HOUSE LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 284. GLOBAL IN-HOUSE LABS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 285. GLOBAL OUTSOURCED PARTNERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 286. GLOBAL OUTSOURCED PARTNERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 287. GLOBAL OUTSOURCED PARTNERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 288. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 289. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 290. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 291. GLOBAL VETERINARY PATHOLOGY LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 292. GLOBAL VETERINARY PATHOLOGY LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 293. GLOBAL VETERINARY PATHOLOGY LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 294. GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 295. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 296. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2017-2032 (USD MILLION)
TABLE 297. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 298. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 299. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 300. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 301. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2017-2032 (USD MILLION)
TABLE 302. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2017-2032 (USD MILLION)
TABLE 303. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2017-2032 (USD MILLION)
TABLE 304. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 305. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2017-2032 (USD MILLION)
TABLE 306. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2017-2032 (USD MILLION)
TABLE 307. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2017-2032 (USD MILLION)
TABLE 308. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2017-2032 (USD MILLION)
TABLE 309. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 310. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2017-2032 (USD MILLION)
TABLE 311. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 312. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 314. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 315. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 316. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 317. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 318. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 319. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 320. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, 2017-2032 (USD MILLION)
TABLE 321. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HOSPITAL LABORATORIES, 2017-2032 (USD MILLION)
TABLE 323. ASIA-PACIFIC IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 324. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 325. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2017-2032 (USD MILLION)
TABLE 326. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 327. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 328. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 329. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 330. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2017-2032 (USD MILLION)
TABLE 331. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2017-2032 (USD MILLION)
TABLE 332. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2017-2032 (USD MILLION)
TABLE 333. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 334. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2017-2032 (USD MILLION)
TABLE 335. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2017-2032 (USD MILLION)
TABLE 336. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2017-2032 (USD MILLION)
TABLE 337. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2017-2032 (USD MILLION)
TABLE 338. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 339. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2017-2032 (USD MILLION)
TABLE 340. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 341. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 342. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 343. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 344. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 345. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 346. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 347. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 348. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY, 2017-2032 (USD MILLION)
TABLE 349. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RENAL & HEPATIC, 2017-2032 (USD MILLION)
TABLE 350. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 351. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY HOSPITAL LABORATORIES, 2017-2032 (USD MILLION)
TABLE 352. NORTH AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 353. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 354. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRODUCT CATEGORY, 2017-2032 (USD MILLION)
TABLE 355. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 356. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY PRIMARY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 357. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SECONDARY ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 358. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY DETECTION SYSTEMS, 2017-2032 (USD MILLION)
TABLE 359. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENS & COUNTERSTAINS, 2017-2032 (USD MILLION)
TABLE 360. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ANCILLARY REAGENTS, 2017-2032 (USD MILLION)
TABLE 361. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY KITS & PANELS, 2017-2032 (USD MILLION)
TABLE 362. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 363. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CHROMOGENIC IHC, 2017-2032 (USD MILLION)
TABLE 364. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY IMMUNOFLUORESCENCE, 2017-2032 (USD MILLION)
TABLE 365. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SIGNAL AMPLIFICATION, 2017-2032 (USD MILLION)
TABLE 366. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY METAL-CONJUGATED IHC, 2017-2032 (USD MILLION)
TABLE 367. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY SPECIMEN TYPE, 2017-2032 (USD MILLION)
TABLE 368. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY FFPE TISSUE, 2017-2032 (USD MILLION)
TABLE 369. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CYTOLOGY SPECIMENS, 2017-2032 (USD MILLION)
TABLE 370. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 371. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 372. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 373. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY RESEARCH & DRUG DISCOVERY, 2017-2032 (USD MILLION)
TABLE 374. LATIN AMERICA IMMUNOHISTOCHEMISTRY MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 375.

Companies Mentioned

Agilent Technologies Inc.
Becton, Dickinson & Company
Bio SB
Bio-Rad Laboratories Inc.
Bio-Techne Corporation
Biocare Medical LLC
Biogenex Laboratories
CANDOR Bioscience GmbH
Cell Signaling Technology, Inc.
Danaher Corporation
Diagnostic BioSystems Inc.
Eagle Biosciences, Inc.
Elabscience Biotechnology Inc.
F. Hoffman-La Roche AG
Genemed Biotechnologies, Inc. =
Histo-Line Laboratories
Lunaphore Technologies SA
Merck KGaA
Miltenyi Biotec B.V. & Co. KG
PerkinElmer Inc.
Rockland Immunochemicals, Inc.
Takara Bio, Inc
Thermofisher Scientific, Inc.

Table Information

Report Attribute	Details
No. of Pages	198
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 3.53 Billion
Forecasted Market Value ( USD ) by 2032	$ 5.07 Billion
Compound Annual Growth Rate	6.1%
Regions Covered	Global
No. of Companies Mentioned	24

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the IHC Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights

Key Group Insights

Key Country Insights

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Immunohistochemistry - Global Strategic Business Report

Immunohistochemistry Market by Product & Service (Antibodies (Type (Primary), Clonality (Monoclonal), Regulatory Class, Reagents, Kits, Instruments (Stainers), Software)), Application (Diagnostics (Cancer), Research, Forensics) - Global Forecast to 2030

Immunohistochemistry (IHC) Market Report 2026

Immunohistochemistry Market Outlook 2026-2034: Market Share, and Growth Analysis by Product Type, Application, End User, Technique

Anti-rabbit Immunohistochemistry Kit Market Report: Trends, Forecast and Competitive Analysis to 2031